Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1856681 | 0.98 | CYP1A2 (0.47) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1855094 | 0.98 | CYP1A2 (0.50) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1859894 | 0.96 | CYP1A2 (0.48) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1853458 | 0.96 | CYP1A2 (0.48) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27379883 | 0.89 | CYP1A2 (0.53) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18916791 | 0.84 | CYP1A2 (0.48) | CYP1A2SMN1; SMN2ALDH1A1POLBGABRR1 | |
| SCHEMBL24872517 | 0.82 | CYP1A2 (0.47) | CYP1A2ALDH1A1L3MBTL1GABRR1KMT2A | |
| SCHEMBL30091889 | 0.82 | L3MBTL1 (0.52) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27258158 | 0.82 | ALDH1A1 (0.44) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23375894 | 0.81 | GABRR1 (0.45) | CYP1A2SMN1; SMN2ALDH1A1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102918027-A | Modulators of the gpr119 receptor and the treatment of disorders related thereto | ARENA PHARM INC | 2013-02-06 | — | — | CN | claimed |
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| CN-101679287-B | Nicotinic acetylcholine receptor modulators | SIENA BIOTECH SPA | 2013-03-27 | — | — | CN | disclosed |
| CN-102918027-A | Modulators of the gpr119 receptor and the treatment of disorders related thereto | ARENA PHARM INC | 2013-02-06 | — | — | CN | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| EP-1991528-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007098826-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2007-09-07 | — | — | WO | disclosed |
| US-5492919-A | IRRITABLE BOWEL DISORDER | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-02-20 | — | — | US | disclosed |
| EP-0596933-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993002677-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-02-18 | — | — | WO | disclosed |
| US-4020163-A | Use of heterocyclic esters of 5H-[1]benzopyrano [3,4-b]pyridines as analgesics | SHARPS ASSOCIATES (US) | 1977-04-26 | — | — | US | disclosed |
| US-3941782-A | Heterocyclic esters of benzopyrans | SHARPS ASSOCIATES (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | CYP1A2 1261/4885MAPK1 1781/4885SMN1; SMN2 2002/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | CYP1A2 2584/4885MAPK1 1513/4885SMN1; SMN2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.